Haleon PLC Sponsored ADR (HLN1N) Stock Price & Analysis
HLN1N Stock Chart & Stats
- Day’s Range
- MXN 170.00 - MXN 193.49
- 52-Week Range
- MXN 150.00 - MXN 205.80
- Previous Close
- MXN 170.00
- Volume
- 63
- Average Volume (3M)
- 1
- Market Cap
- MXN 699.31B
- Enterprise Value
- MXN 51.55B
- Total Cash (Recent Filing)
- MXN 821.01M
- Total Debt (Recent Filing)
- MXN 8.20B
- Price to Earnings (P/E)
- 17.8
- Beta
- -0.12
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 2.75
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.05%
Bulls Say, Bears Say
Bulls Say
Margin Expansion And Productivity Savings
Improving gross and operating margins, supported by identified operating-model savings, indicate that Haleon is strengthening profitability through repeatable productivity actions. This can support earnings growth and provide capacity to reinvest in brands, innovation, and distribution over the next several quarters.
Healthy Cash Generation
Cash flow that closely tracks reported earnings supports the quality of Haleon’s profitability and gives management greater flexibility to fund brand investment, reduce obligations, and return capital. Strong conversion should remain a durable advantage if operating performance continues to improve.
Broad Branded Consumer-health Portfolio
A diversified portfolio across recurring consumer-health categories and multiple distribution channels reduces reliance on any single product or route to market. Established brands and broad retail reach can support repeat purchases, customer recognition, and resilient demand across regions.
Bears Say
Material Absolute Debt Burden
Although leverage improved, the sizeable absolute debt balance can constrain financial flexibility and compete with investment, shareholder returns, or deleveraging for available cash. If revenue growth stays modest, servicing and refinancing obligations may limit management’s ability to respond aggressively.
Growth Outlook Has Softened
The lower growth outlook suggests that Haleon’s near-term expansion is less broad-based than earlier guidance implied. Slower sales growth can reduce operating leverage, make margin improvement more dependent on cost actions, and increase pressure on innovation and commercial investment to sustain momentum.
Respiratory And Regional Exposure
Weakness in respiratory products and challenging markets in the Middle East and Pakistan show that important parts of the portfolio and geographic footprint remain vulnerable. Continued underperformance in these areas could offset strength elsewhere and make consolidated growth more uneven.
Haleon PLC Sponsored ADR News
Haleon’s New Toothpaste Trial Targets Sensitive Teeth And Long‑Term Oral‑Care Growth
Haleon PLC Sponsored ADR ($HLN) announced an update on their ongoing clinical study. Haleon PLC Sponsored ADR (HLN) is sponsoring an 8‑week clinical study titled “An 8‑Week, Randomised, Controlled, Double‑Blind,
HLN1N FAQ
What was Haleon PLC Sponsored ADR’s price range in the past 12 months?
What is Haleon PLC Sponsored ADR’s market cap?
When is Haleon PLC Sponsored ADR’s upcoming earnings report date?
How were Haleon PLC Sponsored ADR’s earnings last quarter?
Is Haleon PLC Sponsored ADR overvalued?
Does Haleon PLC Sponsored ADR pay dividends?
What is Haleon PLC Sponsored ADR’s EPS estimate?
How many shares outstanding does Haleon PLC Sponsored ADR have?
What happened to Haleon PLC Sponsored ADR’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Haleon PLC Sponsored ADR?
What is the TipRanks Smart Score and how is it calculated?
Haleon PLC Sponsored ADR Stock Smart Score
Company Description
Haleon PLC Sponsored ADR
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Brian James McNamara
- Employees
- 24,535
- Website
- www.haleon.com
- Address
- The Heights, Weybridge, SU, KT13 0NY, GB
Haleon PLC Sponsored ADR (HLN1N) Earnings & Revenues
HLN1N Company Deck
HLN1N Earnings Call
Earnings Call SentimentPositive
The call conveyed more positive than negative developments: solid organic growth (3.1%) with sequential improvement, robust margin expansion (gross margin +140 bps; operating margin +120 bps), strong region/product performances (Oral Care, China, India, emerging markets) and continued investment behind digital and innovation. Key headwinds—weak Respiratory (notably cough & cold), regional softness in Europe and the Middle East, and some pricing pressure in Asia—are material but portrayed as cyclical or manageable through productivity and targeted reinvestment. Management maintained guidance (3%–5% organic growth) and expressed confidence in a stronger H2.
View all MX:HLN1N earnings summariesHLN1N Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 4 |
| Technical Analysis | 3 | 2 | 3 |
| Moving Averages | 11 | 0 | 1 |
